Alcolase
Develops an enzyme-based treatment for alcohol intolerance, backed by early-stage investors to advance its therapeutic approach.
Overview
Alcolase is developing an enzyme treatment aimed at alcohol intolerance, positioning the company in biotechnology rather than core AI. Its work targets people affected by alcohol intolerance and focuses on a therapeutic approach based on enzyme activity. The company raised about $2 million across one undisclosed round, described as a €1.5 million financing backed by Ada Ventures and Antler. The capital is intended to support development of its enzyme treatment.
Funding History
Ada Ventures, Antler back Alcolase in €1.5M round to develop enzyme treatment for alcohol intolerance
Frequently Asked Questions
- How much has Alcolase raised in total?
- Alcolase has raised a total of $2M across 1 funding round.
- Who are Alcolase's investors?
- Alcolase's investors include Undisclosed.
- What does Alcolase do?
- Alcolase is developing an enzyme treatment aimed at alcohol intolerance, positioning the company in biotechnology rather than core AI. Its work targets people affected by alcohol intolerance and focuses on a therapeutic approach based on enzyme activity. The company raised about $2 million across one undisclosed round, described as a €1.5 million financing backed by Ada Ventures and Antler. The capital is intended to support development of its enzyme treatment.
- Where is Alcolase headquartered?
- Alcolase is headquartered in San Francisco, CA.
Investors
Related Insights
The definitive guide to AI startup funding in 2026 — from pre-seed through IPO, covering valuation mechanics, timelines, investor expectations, and how AI companies differ from traditional tech startups.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.